信達生物(1801.HK)新藥IBI939獲批臨牀 擬用於治療晚期腫瘤
格隆匯1月6日丨Insight 數據庫顯示,信達生物製藥(1801.HK)的1類新藥IBI939獲批臨牀,擬用於治療晚期腫瘤(血液腫瘤和實體瘤)。IBI939是由信達生物研發的國內首個TIGIT抗體。據瞭解,TIGIT 是一款免疫檢查點抑制劑,主要在T細胞和NK細胞表面表達,在它們的激活和成熟過程中起重要作用。TIGIT在腫瘤免疫抑制中的作用和 PD-1/PD-L1 類似。多項臨牀前試驗結果表明anti-TIGIT抗體和anti-PD-1/PD-L1抗體可發揮協同抗腫瘤作用。此次信達生物IBI939獲批臨牀將進一步提升該項目潛在價值,繼續夯實公司在抗腫瘤領域的領先作用。當前信達生物在研管線豐富,包括PD-1、CD20、VEGF、TNF-α等臨牀後期重磅靶點,以及臨牀早期的創新大分子CTLA-4、RANKL、OX40、PCSK9、CD47等創新靶點,同時公司還儲備了圍繞PD-1/PD-L1開展的雙特異性抗體品種,公司研發管線梯隊完整,多個項目的臨牀進展迅速,目前PD-1單抗達伯舒已經上市並進入國家醫保目錄。另外還有16個產品進入臨牀研究,3個產品申報上市並進入優先審評,有望在2020年上市。產品組合豐富,在創新醫藥領域前景可期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.